Zobrazeno 1 - 10
of 359
pro vyhledávání: '"Chunsheng Kang"'
Autor:
Zihe Zhang, Yongwen Li, Ruifeng Shi, Chaoyi Jia, Songlin Xu, Guangsheng Zhu, Peijun Cao, Hua Huang, Xuanguang Li, Hongbing Zhang, Minghui Liu, Chen Chen, Hongyu Liu, Chunsheng Kang, Jun Chen
Publikováno v:
Cell Death and Disease, Vol 15, Iss 9, Pp 1-14 (2024)
Abstract Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI) approved for patients with EGFR T790M resistance mutations as first- or second-line treatment of EGFR-positive patients. Resistanc
Externí odkaz:
https://doaj.org/article/6cd58d2ae3984a0ea93766d76679bcb3
Autor:
Xiaoteng Cui, Dawei Huo, Qixue Wang, Yunfei Wang, Xiaomin Liu, Kai Zhao, Yongping You, Junxia Zhang, Chunsheng Kang
Publikováno v:
Cell Death and Disease, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Extracellular matrix (ECM) remodeling has been implicated in the tumor malignant progression and immune escape in glioblastoma (GBM). Runt-related transcription factor 1 (RUNX1) is a vital transcriptional factor for promoting tumorigenesis a
Externí odkaz:
https://doaj.org/article/3bb92f82887f4710a22f6ec3ae2ae5a3
Autor:
Xiaoteng Cui, Jixing Zhao, Guanzhang Li, Chao Yang, Shixue Yang, Qi Zhan, Junhu Zhou, Yunfei Wang, Menglin Xiao, Biao Hong, Kaikai Yi, Fei Tong, Yanli Tan, Hu Wang, Qixue Wang, Tao Jiang, Chuan Fang, Chunsheng Kang
Publikováno v:
Cancer Communications, Vol 43, Iss 12, Pp 1326-1353 (2023)
Abstract Background Metabolism reprogramming plays a vital role in glioblastoma (GBM) progression and recurrence by producing enough energy for highly proliferating tumor cells. In addition, metabolic reprogramming is crucial for tumor growth and imm
Externí odkaz:
https://doaj.org/article/00cb3e09a93e47169bf92b48fab6f99a
Autor:
Junhu Zhou, Fei Tong, Jixing Zhao, Xiaoteng Cui, Yunfei Wang, Guangxiu Wang, Chunsheng Kang, Xiaomin Liu, Qixue Wang
Publikováno v:
Cancer Biology & Medicine, Vol 20, Iss 5, Pp 385-400 (2023)
Objective: Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively-activated mutation of EGFR that contributes to the malignant progression of glioblastoma multiforme (GBM). Temozolomide (TMZ) is a standard chemotherapeutic for GB
Externí odkaz:
https://doaj.org/article/8a1721fee85e4c6681a6b50fdfad6c5a
Publikováno v:
Cancer Biology & Medicine, Vol 20, Iss 5, Pp 344-352 (2023)
Malignant gliomas are known to be one of the most difficult diseases to diagnose and treat because of the infiltrative growth pattern, rapid progression, and poor prognosis. Many antitumor drugs are not ideal for the treatment of gliomas due to the b
Externí odkaz:
https://doaj.org/article/a04f04e369ad47518ba0d9988f3f6328
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/44a5000af42e40b48da4be2d327038ab
Autor:
Can Xu, Jixing Zhao, Jia Song, Menglin Xiao, Xiaoteng Cui, Lei Xin, Jianglong Xu, Yuhao Zhang, Kaikai Yi, Biao Hong, Fei Tong, Shaohui Tian, Yanli Tan, Chunsheng Kang, Chuan Fang
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Glioblastoma (GBM) is the most common and lethal type of primary malignant central nervous system (CNS) tumor with an extremely poor prognosis, and the mesenchymal subtype of GBM has the worst prognosis. Here, we found that lncRNA PRADX was overexpre
Externí odkaz:
https://doaj.org/article/63cd2b606ac946ee98f831c0608f7984
Autor:
Yingbin Xie, Luyue Chen, Junhu Zhou, Qixue Wang, Chao Yang, Can Xu, Xiangyu Fan, Yanli Tan, Yanan Wang, Chunsheng Kang, Chuan Fang
Publikováno v:
Cancer Biology & Medicine, Vol 17, Iss 3, Pp 664-675 (2020)
Objective: Mesenchymal subtype of glioblastoma (mesGBM) is a refractory disease condition characterized by therapeutic failure and tumor recurrence. Hyperactive transforming growth factor-β (TGF-β) signaling could be a signature event in mesGBM, wh
Externí odkaz:
https://doaj.org/article/f42c911e965f41d899373e9e6e2f1929
Autor:
Chao Yang, Yanli Tan, Hongzhao Qi, Junhu Zhou, Lixia Long, Qi Zhan, Yunfei Wang, Xubo Yuan, Chunsheng Kang
Publikováno v:
Cancer Biology & Medicine, Vol 17, Iss 2, Pp 433-443 (2020)
Objective: The introduction of therapeutic antibodies (tAbs) into clinical practice has revolutionized tumor treatment strategies, but their tumor therapy efficiency is still far below expectations because of the rapid degradation and limited tumor a
Externí odkaz:
https://doaj.org/article/ab95fdffcaef4d1883b65426042e766f
EGFR-vIII downregulated H2AZK4/7AC though the PI3K/AKT-HDAC2 axis to regulate cell cycle progression
Autor:
Hongyu Zhao, Yunfei Wang, Chao Yang, Junhu Zhou, Lin Wang, Kaikai Yi, Yansheng Li, Qixue wang, Jin Shi, Chunsheng Kang, Liang Zeng
Publikováno v:
Clinical and Translational Medicine, Vol 9, Iss 1, Pp 1-15 (2020)
Abstract Background The EGFR-vIII mutation is the most common malignant event in GBM. Epigenetic reprogramming in EGFR-activated GBM has recently been suggested to downregulate the expression of tumour suppressor genes. Histone acetylation is importa
Externí odkaz:
https://doaj.org/article/6cc6edefc01140a9910ff5fb873dd0ea